Biophytis SA (FR:ALBPS) has released an update.
Biophytis SA, a clinical-stage biotech company, has extended its bond financing agreement with investment fund Atlas to secure up to €16 million for advancing its clinical programs in obesity and Duchenne Muscular Dystrophy. The terms of the deal aim to minimize share dilution and extend the company’s financial runway into late 2024. Biophytis is also pursuing partnerships and additional funding to support the upcoming clinical trials.
For further insights into FR:ALBPS stock, check out TipRanks’ Stock Analysis page.